Trials Currently Open For Enrollment

AS OF OCTOBER 2011 THE FOLLOWING TRIALS/STUDIES ARE OPEN FOR ENROLLMENT.  CONTACT ONE OF OUR RESEARCH COORDINATORS FOR MORE INFORMATION AT 913-894-1500

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Title:  An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis

Purpose:  The purpose of this study is to determine the safety and tolerability of ELND002 in patients with relapsing forms of secondary progressive multiple sclerosis (SPMS) or relapsing-remitting multiple sclerosis (RRMS).

http://www.clinicaltrials.gov/ct2/show/NCT01144351?term=elan+multiple+sclerosis&rank=3

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (TOPIC)

Title:  An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis

Purpose:  The primary objective is to demonstrate the effect of teriflunomide (14 mg/day and 7 mg/day) compared to placebo for reducing conversion of patients presenting with their first clinical episode consistent with Multiple Sclerosis (MS) to clinically definite MS.

http://www.clinicaltrials.gov/ct2/show/NCT00622700?term=sanofi+aventis&rank=4

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Title:  A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis

Purpose:  The ACCLAIM study is testing whether the medication "abatacept" can be of benefit to patients with relapsing-remitting multiple sclerosis. Although abatacept is an investigational medication for MS, it is not a new drug - it has been approved by the FDA to treat rheumatoid arthritis.
http://www.clinicaltrials.gov/ct2/show/NCT01116427?term=midamerica+neuroscience+institute&rank=4

JCV Antibody Program (STRATIFY-2)

Title:  JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2

Purpose:  Define the sero prevalence of JCV Antibody in the MS population and potentially stratify patients into lower or higher risk for developing PML based on antibody status.

http://www.clinicaltrials.gov/ct2/show/NCT01070836?term=biogen+idec+ms&recr=Open&rank=16

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Title:  A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Purpose:  To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).

http://www.clinicaltrials.gov/ct2/show/NCT01359566?term=xenoport+ms&rank=2

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Title:  A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Purpose:  This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in patients with primary progressive multiple sclerosis. Eligible patients will be randomized 2 : 1 to receive either ocrelizumab (300 mg intravenously on Days 1 and 15 of the first treatment cycle, followed by 600 mg iv every 24 weeks) or placebo. The blinded treatment period will be at least 120 weeks, followed by open label treatment for patients in both groups who in the opinion of the investigator could benefit from further or newly initiated ocrelizumab treatment. Anticipated time on study treatment is up to 5.5 years.

http://www.clinicaltrials.gov/ct2/show/NCT01194570?term=roche+ms&rank=3

A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis

Title:  A Randomized, Double-Blind (With Respect To Ocrelizumab Dose) And Rater-Blind (Versus Comparator), Parallel-Group Study To Evaluate The Efficacy And Safety Of Two Doses Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif) In Patients With Relapsing Multiple Sclerosis

Purpose:  This randomized, double-blind (with respect to ocrelizumab dose) and rater-blind (versus comparator), parallel-group study will evaluate the safety and efficacy of ocrelizumab in comparison with interferon beta-1a in patients with relapsing multiple sclerosis. Patients will be randomized to receive either ocrelizumab 600 mg or 400 mg intravenously every 24 weeks or interferon beta-1a 44mcg subcutaneously three times weekly. Anticipated time on study treatment is 96 weeks. In an ocrelizumab treatment extension phase all eligible patients will have the option to receive ocrelizumab.

http://www.clinicaltrials.gov/ct2/show/NCT01247324?term=roche+ms&rank=3

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Title:  A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients With Multiple Sclerosis

Purpose:  The objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses of AVP-923 capsules in the treatment of central neuropathic pain in patients with multiple sclerosis.

http://www.clinicaltrials.gov/ct2/show/NCT01324232?term=avanir&rank=3